(Q33967061)

30 July 2017

Decline in the AIDS and death rates in the EuroSIDA study: an observational study (English)

1 reference

30 July 2017

0 references

3

C Katlama

1 reference

30 July 2017

7

B Knysz

1 reference

Antonella d'Arminio Monforte

30 July 2017

series ordinal

6

object named as

A d'Arminio Monforte

1 reference

30 July 2017

10

J D Lundgren

1 reference

30 July 2017

4

O Kirk

1 reference

30 July 2017

5

P Reiss

1 reference

30 July 2017

1

A Mocroft

1 reference

30 July 2017

11

EuroSIDA study group

1 reference

30 July 2017

B Ledergerber

2

1 reference

30 July 2017

M Dietrich

series ordinal

8

1 reference

30 July 2017

A N Phillips

series ordinal

9

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 July 2003

1 reference

30 July 2017

1 reference

30 July 2017

362

1 reference

30 July 2017

22-29

1 reference

30 July 2017

9377

1 reference

Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913802-0

7 January 2021

AIDS across Europe, 1994-98: the EuroSIDA study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913802-0

7 January 2021

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913802-0

7 January 2021

Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913802-0

7 January 2021

Changes in use of antiretroviral therapy in regions of Europe over time

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913802-0

7 January 2021

HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913802-0

7 January 2021

Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913802-0

7 January 2021

Predictors of Virological Success and Ensuing Failure in HIV-Positive Patients Starting Highly Active Antiretroviral Therapy in Europe

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913802-0

7 January 2021

British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913802-0

7 January 2021

Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913802-0

7 January 2021

Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. EuroSIDA Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913802-0

7 January 2021

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913802-0

7 January 2021

Predictors of long-term increase in CD4(+) cell counts in human immunodeficiency virus-infected patients receiving a protease inhibitor-containing antiretroviral regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913802-0

7 January 2021

Final analysis of the Trilège induction-maintenance trial: results at 18 months

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913802-0

7 January 2021

Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913802-0

7 January 2021

The values of quantitative serum HIV-1 RNA levels and CD4 cell counts for predicting survival time among HIV-positive individuals with CD4 counts of < or = 50 x 10(6) cells/l

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913802-0

7 January 2021

HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913802-0

7 January 2021

A Clinically Prognostic Scoring System for Patients Receiving Highly Active Antiretroviral Therapy: Results from the EuroSIDA Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913802-0

7 January 2021

Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913802-0

7 January 2021

Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913802-0

7 January 2021

Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913802-0

7 January 2021

Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913802-0

7 January 2021

Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913802-0

7 January 2021

Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987-1999

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913802-0

7 January 2021

Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913802-0

7 January 2021

Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913802-0

7 January 2021

Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913802-0

7 January 2021

Improved survival among HIV-infected individuals following initiation of antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913802-0

7 January 2021

10.1016/S0140-6736(03)13802-0

Identifiers

DOI

1 reference

30 July 2017

1 reference